THE EFFECT OF MONTHLY IBANDRONATE ON BONE MINERAL DENSITY AND BONE TURNOVER MARKERS IN PATIENTS WITH HAEMOPHILIA A OR B AND INCREASED RISK FOR FRACTURE

Panagiotis Anagnostis1, Timoleon-Achilleas Vyzantiadis1, Maria Charizopoulou4, Fotini Adamidou1, Spyridon Karras5, Arisitidis Slavakis6, Vasilia Garipidou2, Sofia Vakalopoulou2

1Department of Endocrinology, Hippokration Hospital of Thessaloniki, Greece
2Haemophilia Center of Northern Greece, 2nd Propedeutic Department of Internal Medicine, Aristotle University, Hippokration Hospital, Thessaloniki, Greece
31st Department of Microbiology, Medical School, Aristotle University, Thessaloniki, Greece
4Department of Psychology, School of Philosophy, Aristotle University, Thessaloniki, Greece
5Department of Endocrinology and Metabolism, Agios Pavlos General Hospital, Thessaloniki, Greece
6Department of Biochemistry, Hormone Assay Laboratory, Hippokration Hospital, Thessaloniki, Greece

Introduction

- Haemophilia A and B has been associated with increased prevalence of low bone mineral density (BMD).
- However, no study has so far evaluated the effects of any anti-osteoporotic therapy on BMD.

Aims

- The primary endpoint was to estimate the effect of 12-month therapy of oral ibandronate 150mg/month on BMD in patients with haemophilia A and B.
- Secondary endpoint was its effect on bone turnover markers (BTM), including serum C-terminal telopeptide of type 1 collagen (sCTX) and tartrate-resistant acid phosphatase band 5b (as markers of bone resorption), osteocalcin and bone-specific alkaline phosphatase (as markers of bone formation).

Patients and methods

- This was a prospective open-label intervention study.
- Per os ibandronate (150 mg/month) was given to adult patients with T-score <-2.5 SD or Z-score <-2 and/or increased risk of fracture according to FRAX model were included.
- All patients received 1000 mg/d calcium carbonate with 800 IU/d cholecalciferol.

Exclusion criteria:
- Active peptic ulcer, esophagitis or severe gastrointestinal reflux
- Severe diseases affecting bone metabolism, such as primary hyperparathyroidism, hyperthyroidism, hypogonadism
- Renal failure (e-GFR < 30 ml/min)
- Severe vitamin D deficiency (25-OHD <10ng/ml)
- Any anti-osteoporotic medication the past 12 months

Results

- 10 males (aged 43.7±13.8 years, 7 with haemophilia A) were included.
- Ibandronate resulted in a significant increase in lumbar BMD [from 0.885±0.162 g/cm² to 0.926±0.177 g/cm², p=0.011 (+4.9%, greater than the least significant change provided for the DXA device)].
- No significant change in BMD of total hip (from 0.717±0.128 to 0.729±0.153 g/cm², p=0.963) or neck (0.741±0.135 to 0.761±0.146 g/cm², p=0.952) was noticed.
- Ibandronate led to a significant decrease in sCTX [from 0.520±0.243 to 0.347±0.230 ng/ml, p=0.042 (-29.9%, compared with baseline levels)].
- No significant change in the other BTM was observed.
- Ibandronate was generally well-tolerated.
- No fractures were reported.

Conclusions

- In the first study conducted so far evaluating the effect of bisphosphonates in patients with haemophilia and increased fracture risk, ibandronate significantly improved BMD in lumbar spine and reduced bone resorption.
- Its effect on hip BMD and bone formation markers was not significant. This may be attributed to the small number of patients, based on the strict selection criteria.

References

Anagnostis et al. Thromb Haemost 2012;17:545-551
Katsarou G, Ann Hematol 2010;89:67-74